Advertisement

Topics

Disabling critical 'node' revs up attack when cancer immunotherapies fall short

07:36 EST 1 Dec 2016 | Medical Xpress

An existing drug known as a JAK inhibitor may help patients who don't respond to the so-called checkpoint inhibitor immunotherapy drugs overcome that resistance, suggests a new preclinical study published online in Cell today by Penn Medicine researchers. Importantly, the results demonstrate that shutting down the interferon pathway, shown here to be critical to a tumor's resistance to immunotherapy, with a JAK inhibitor may improve checkpoint inhibitor drugs and even bypass the need for combinations of these drugs, which often come with serious side effects.

Original Article: Disabling critical 'node' revs up attack when cancer immunotherapies fall short

NEXT ARTICLE

More From BioPortfolio on "Disabling critical 'node' revs up attack when cancer immunotherapies fall short"

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...